[News in diabetology 2018].
Diabetes is a rapidly evolving discipline, numerous new molecules and technologies are available. This allows for a better follow up of our patients with type 1 and type 2 diabetes. Moreover, every new molecule devoted to treat type 2 diabetes must undergo a cardiovascular safety study. In recent years, some of these studies proved to be beneficial for some of our patients. Nevertheless, this pharmacological plethora is paradoxically associated with clinical inertia as general practitioners may be in trouble finding the right medication. This article will highlight novelties in the field of diabetes during the year 2018.